The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
South Beach challenged rival AriZona in sales and was pursuing Snapple for leadership in the new age drink category. Less than pleased, rival AriZona slapped the company with a lawsuit claiming that SoBe had copied its bottle design or stolen trade secrets. Then Judge Sonia Sotomayor ruled in SoBe's favor denying a preliminary injunction. Legal action proceeded and persisted on the federal and state level until 2007, long after the company had been sold to PepsiCo. In 2007, the court dismissed all AriZona claims on summary judgement In 2001, Bello was named Ernst and Young's National Entrepreneur of the Year in the Consumer Products category for his accomplishments at SoBe.
== Treatment == MCTD has no specific treatment. Management should address the individual's primary issues, such as arthritis, skin disease, or visceral involvement. Low-dose glucocorticoids, nonsteroidal anti-inflammatory medications, hydroxychloroquine, or a combination of these therapies can effectively treat many patients. Fever, tiredness, unspecific arthralgias, or myalgias are commonly treated with nonsteroidal anti-inflammatory medications (NSAIDs), hydroxychloroquine, or a low dose of prednisone, depending on the severity. Mild joint involvement can be effectively treated with NSAIDs, hydroxychloroquine, and oral prednisone. Methotrexate has been observed to be useful in more severe cases. If methotrexate is contraindicated, alternative disease-modifying medications for RA, such as leflunomide or azathioprine, may be used. High dosages of corticosteroids are typically effective in treating acute severe myositis. Topical steroids, prednisone, and/or hydroxychloroquine are useful in treating SLE-like skin rash, oral ulcers, and photosensitivity. Steroid treatment is often effective in treating sclerodermatous skin symptoms. Raynaud's phenomenon in MCTD typically responds to vasodilator therapy such as calcium channel blockers, as well as preventive measures including avoiding cold temperatures, smoking, and sympathomimetic drugs. Warming and protecting the fingers are also important. Recent breakthroughs have increased the therapy choices available to people with pulmonary hypertension.
And it created a Carbon Mitigation Credit, funded by a surcharge added to energy bills, to subsidize the operation of nuclear power plants during times when they would ordinarily be unprofitable. The law also requires nuclear power plant operators to send a credit back to ratepayers when demand for nuclear energy, and by extension energy rates, rise, which has given ratepayers a partial break on their monthly payments at various times since the law passed.
In December 2008, the 3d BCT deployed to Baghdad, Iraq and redeployed to Ft. Bragg in November 2009. In August 2009, 1st BCT deployed once again to Iraq and redeployed late July 2010. During the months of August and September 2009, 4th BCT deployed again to Afghanistan and returned in August 2010 having lost 38 soldiers. In May 2011 1–505 (Task Force 1 Panther) deployed to Afghanistan in support of Operation Enduring Freedom. Dispersed throughout the country, 1st battalion was attached to various Special Operations elements. 1st battalion redeployed to Fort Bragg, NC in February 2012 having lost two paratroopers. The 2d Brigade deployed to the Al Anbar Governorate in Iraq in May 2011, for the last time, as part of Operation New Dawn. Its mission was to advise, train and assist the Iraqi Armed Forces and Ministry of the Interior forces, as part of the withdrawal of United States Forces – Iraq. Elements of 2d Brigade were among the last US combat units to withdraw from Baghdad. The brigade suffered the loss of the last American service member in Iraq, SPC. David E. Hickman, on 14 November 2011. They were part of the long convoy of equipment and troops who exited Iraq into Kuwait as OIF came to an end.
=== Other impacts === In 1985, Henry Waxman, an American politician, called for a U.S. government inquiry into the Bhopal disaster, which resulted in U.S. legislation regarding the accidental release of toxic chemicals in the United States.
Sources: en.wikipedia.org
== Synthesis, basic properties, and structure == The carbon atom in cyanogen bromide is bonded to bromine by a single bond and to nitrogen by a triple bond (i.e. Br−C≡N). The compound is linear and polar, but it does not spontaneously ionize in water. It dissolves in both water and polar organic solvents. Cyanogen bromide can be prepared by oxidation of sodium cyanide with bromine, which proceeds in two steps via the intermediate cyanogen ((CN)2):
=== Australian refugee advertisement === In 2002, Nando's ran an advertising campaign in Australia based around a political controversy regarding the mandatory detention of refugees. The detainees had been waging a hunger strike campaign, even resorting to sewing their lips closed. Nando's adverts proclaimed that the strikers "decided to unsew their lips after hearing the news that with every Nando's quarter chicken combo, Nando's are giving away an extra quarter chicken free." Melbourne's Sphere Advertising said that the ad was designed to spark controversy, saying that they knew that "there's a section of our audience that's going to be uncomfortable... but we want to evoke a response."
==== Czech ==== Catholic Womens Fraternal of Texas - Founded on September 16, 1894, by Czech Catholic women in the Yoakum and Hallettsville area of Texas. Incorporated in 1927. Headquartered in Austin. Had 24,000 in 1972 and 25,000 in 1977. Membership is now open to people of both genders, irrespective of religion or ethnic background. Junior membership is available for those 17 and under. Has sponsored Newman Clubs at UT and A&M as well as a clerical endowment fund for priest education, the Czech Christian Academy in Rhome, Texas, Right to Life, Radio Free Europe/Radio Liberty as well as other charitable, community and Catholic projects. CSA Fraternal Life - Founded on March 4, 1854, as the Czecho-Slovak Protective Society. On January 1, 1933, merged with the Society of Taborites, Bohemian-Slavonic Fraternal Benefit Union, the Bohemian-Slavonic Union and the Bohemian American Foresters. The organization changed its name to the Czechoslovak Society of America but maintained the original 1854 charter. The Unity of Czech Ladies and Men was absorbed in 1977. According to its current constitution, membership is open to "Any person of good character and who subscribes to the purpose for which the Society is organized and meets all requirements for membership established by the Society." Had 52,000 members in the late 1960s, 50,000 in 1979 and 30,000 in 1990. Its motto was "Equality - Harmony - Fraternity". Its non-secret elaborate rituals included an altar, passwords, and knocks.
== Patient characteristics == To determine the patient's suitability for undergoing a rhinoplasty procedure, the surgeon clinically evaluates them with a complete medical history (anamnesis) to determine their physical and psychological health. The prospective patient must explain to the physician–surgeon the functional and aesthetic nasal problems that they have. The surgeon asks about the ailments' symptoms and their duration, past surgical interventions, allergies, drugs use and drugs abuse (prescription and commercial medications), and a general medical history. Furthermore, additional to physical suitability is psychological suitability—the patient's psychological motive for undergoing nose surgery is critical to the surgeon's pre-operative evaluation of the patient. The complete physical examination of the rhinoplasty patient determines if he or she is physically fit to undergo and tolerate the physiologic stresses of nose surgery. The examination comprehends every existing physical problem, and a consultation with an anaesthesiologist, if warranted by the patient's medical data. Specific facial and nasal evaluations record the patient's skin-type, existing surgical scars, and the symmetry and asymmetry of the aesthetic nasal subunits. The external and internal nasal examination concentrates upon the anatomic thirds of the nose—upper section, middle section, lower section—specifically noting their structures; the measures of the nasal angles (at which the external nose projects from the face); and the physical characteristics of the naso-facial bony and soft tissues.
Sources: en.wikipedia.org
A recombinant fusion protein is a protein created through genetic engineering of a fusion gene. This typically involves removing the stop codon from a cDNA sequence coding for the first protein, then appending the cDNA sequence of the second protein in frame through ligation or overlap extension PCR. That DNA sequence will then be expressed by a cell as a single protein. The protein can be engineered to include the full sequence of both original proteins, or only a portion of either. If the two entities are proteins, often linker (or "spacer") peptides are also added, which make it more likely that the proteins fold independently and behave as expected. Especially in the case where the linkers enable protein purification, linkers in protein or peptide fusions are sometimes engineered with cleavage sites for proteases or chemical agents that enable the liberation of the two separate proteins. This technique is often used for identification and purification of proteins, by fusing a GST protein, FLAG peptide, or a hexa-his peptide (6xHis-tag), which can be isolated using affinity chromatography with nickel or cobalt resins. Di- or multimeric chimeric proteins can be manufactured through genetic engineering by fusion to the original proteins of peptide domains that induce artificial protein di- or multimerization (e.g., streptavidin or leucine zippers). Fusion proteins can also be manufactured with toxins or antibodies attached to them in order to study disease development.
==== Analysis of biological fluids ==== The GC-EI-MS can be incorporated for the analysis of biological fluids for several applications. One example is the determination of thirteen synthetic pyrethroid insecticide molecules and their stereoisomers in whole blood. This investigation used a new rapid and sensitive electron ionization-gas chromatography–mass spectrometry method in selective ion monitoring mode (SIM) with a single injection of the sample. All the pyrethroid residues were separated by using a GC-MS operated in electron ionization mode and quantified in selective ion monitoring mode. The detection of specific residues in blood is a difficult task due to their very low concentration since as soon as they enter the body most of the chemicals may get excreted. However, this method detected the residues of different pyrethroids down to the level 0.05–2 ng/ml. The detection of this insecticide in blood is very important since an ultra-small quantity in the body is enough to be harmful to human health, especially in children. This method is a very simple, rapid technique and therefore can be adopted without any matrix interferences. The selective ion monitoring mode provides detection sensitivity up to 0.05 ng/ml. Another application is in protein turnover studies using GC-EI-MS. This measures very low levels of d-phenylalanine which can indicate the enrichment of amino acid incorporated into tissue protein during studies of human protein synthesis.
== Name and History == The first description of this enzyme was provided by Schack, who named it papaya peptidase A. The same enzyme has since been given a number of different names, including papaya peptidase II, papaya proteinase III and papaya proteinase. The name caricain was recommended by NC-IUBMB in 1992.
== Interactions == Icodextrin can mimic increased blood glucose levels, depending on the used testing system. Specifically, glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase (GDO) based tests can erroneously show high blood glucose in patients that have been treated with icodextrin.
=== Pharmacokinetics === Carteolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier. This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.